(Q30452178)

21 June 2017

Update on molecular findings, management and outcome in low-grade gliomas (English)

1 reference

21 June 2017

T David Bourne

1

1 reference

21 June 2017

David Schiff

series ordinal

2

1 reference

21 June 2017

language of work or name

English

0 references

publication date

2 November 2010

1 reference

21 June 2017

Nature Reviews Neurology

1 reference

21 June 2017

6

1 reference

21 June 2017

695-701

1 reference

21 June 2017

12

1 reference

Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas.

21 June 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

p14ARF deletion and methylation in genetic pathways to glioblastomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

A different view on DNA amplifications indicates frequent, highly complex, and stable amplicons on 12q13-21 in glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

What is an oligodendroglioma?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Fluorescence in situ hybridization (FISH) in diagnostic and investigative neuropathology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Influence of O6-methylguanine-DNA methyltransferase activity on chloroethylnitrosourea chemotherapy in brain tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

MGMT gene silencing and benefit from temozolomide in glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

MGMT methylation: a marker of response to temozolomide in low-grade gliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Molecular markers of prognosis in astrocytic tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Clinical and molecular characteristics of malignant transformation of low-grade glioma in children.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

PTEN promoter methylation in sporadic thyroid carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

PTEN expression in non–small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Investigation of MMAC/PTEN gene mutations and protein expression in low grade gliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

New insight into BRAF mutations in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

An integrated genomic analysis of human glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Analysis of the IDH1 codon 132 mutation in brain tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

IDH1 and IDH2 mutations in gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Recurring mutations found by sequencing an acute myeloid leukemia genome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Monoclonal antibody specific for IDH1 R132H mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Surgery Insight: the role of surgery in the management of low-grade gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Correlation between genetic alteration and long‐term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Survival analysis of presumptive prognostic markers among oligodendrogliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Molecular pathology and clinical characteristics of oligodendroglial neoplasms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Reclassification of oligoastrocytomas by loss of heterozygosity studies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Phase II study of protracted daily temozolomide for low-grade gliomas in adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Retrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Low-grade gliomas in older patients: a retrospective analysis of prognostic factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.159

Immunocytochemical mapping of the phosphatase and tensin homolog (PTEN/MMAC1) tumor suppressor protein in human gliomas

31 March 2020

1 reference

12 December 2020

Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.

1 reference

12 December 2020

Promoter Hypermethylation of the DNA Repair Gene O6‐Methylguanine‐DNA Methyltransferase is an Independent Predictor of Shortened Progression Free Survival in Patients with Low‐grade Diffuse Astrocytomas

1 reference

12 December 2020

Characterisation of molecular alterations in microdissected archival gliomas.

1 reference

12 December 2020

Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival.

1 reference

12 December 2020

Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene

1 reference

12 December 2020

Pten signaling in gliomas

1 reference

12 December 2020

O6-methylguanine-DNA methyltransferase in human brain tumors detected by activity assay and monoclonal antibodies.

1 reference

12 December 2020

10.1038/NRNEUROL.2010.159

Identifiers

DOI

1 reference

Dimensions Publication ID

21 June 2017

0 references

1 reference